FDA Approves YUVIWEL — Ascendis Pharma Endocrinology, Inc.

# FDA Approves Ascendis Pharma's YUVIWEL (navepegritide), Marking Entry Into Growth Hormone Deficiency Market Ascendis Pharma Endocrinology, Inc. received FDA approval for YUVIWEL (navepegritide) on February 27, 2026, expanding the company's endocrinology portfolio and positioning it to compete in the growth hormone secretagogue market. The approval presents significant revenue opportunities for Ascendis as navepegritide addresses an underserved patient population and could establish a new standard